DKDev Karan

Dev Karan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dev Karan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prostate Cancer Immunotherapy: An Evolving Field

    by Mehmood Hashmi, Dev Karan, Sneha Phadke, Yogen Saunthararajah, Suman Kambhampati, Peter Van Veldhuizen

    In United States, prostate cancer is the most common cancer diagnosis (excluding dermatological malignancies) and the second leading cause of cancer related mortality in men [1]. Early stage prostate cancer has an indolent course; however local tumor progression and aggressive metastatic disease may develop in the long term [2]. Androgen deprivation therapy provides disease control for a substantial period of time; however the vast majority eventually progress [3, 4]. In hormone refractory cases, chemotherapy with docetaxel and prednisone led to a superior survival and quality of life [5]. This combination remained as the predominant first line of chemotherapeutic option for a significant period of time. Only recently have new advances in chemotherapeutic, anti-androgen and other novel therapeutic options made it into the clinic. Sipuleucel-T in patients with castration-resistant metastatic prostate cancer demonstrated a reduction in the risk of death [6]. The sipuleucel-T trial results have helped demonstrate a proof of concept of the potential of immunotherapy in prostate cancer but widespread acceptance of its use has been tempered by the time limited survival advantage of only four months. Therefore, we continue to need novel agents and combination strategies which build on this initial success. Several other inter-related patho-physiological mechanisms like inflammation and genetic/epigenetic modulation are under investigation in prostate cancer which could have further implications in the development of these new immunotherapeutic preventive and treatment strategies [7, 8]. In this article we will give an overview about the role and link of inflammation, epigenetic modulation and immune modulation in the development and treatment of prostate cancer. It is imperative that new approaches that further define immune responsiveness and identify which patients are most likely to benefit. With the increasing availability of novel agents, future advances will also lie in innovative combination strategies.

  • Combination Immunotherapy with Prostate GVAX and Ipilimumab: Safety and Toxicity

    by Dev Karan, Peter Van Veldhuizen

    Evaluation of: van den Eertwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509 – 517 (2012). A significant interest in the development of therapeutic cancer vaccines over the last decade has led to an improvement in overall survival of cancer patients in several clinical trials. As a result, two active immunotherapy agents, sipuleucel-T and ipilimumab, have been approved by the US FDA for the treatment of prostate cancer and melanoma, respectively. GVAX(®) cellular vaccine (Cell Genesysis, Inc., CA, USA) is another active immunotherapy agent targeting prostate cancer and it has been well studied in various clinical trials. The current publication, by van den Eertwegh et al., demonstrated a combination of two active immunotherapy approaches, using GVAX and ipilimumab for the treatment of metastatic castration-resistant prostate cancer. While GVAX is designed to amplify the antitumor response specific to prostate cancer cells, ipilimumab contributes to T-cell activation. Thus, the authors presented the possibility of augmenting antitumor T-cell activity in two different ways. They successfully demonstrated a tolerable dose and safety profile of ipilimumab in combination with GVAX for patients with metastatic castration-resistant prostate cancer. However, further studies of such immunotherapy combinations and detailed analysis of their immunological effects are needed to observe clinical benefit.


  • Cancer immunotherapy: a paradigm shift for prostate cancer treatment

    by Dev Karan, Jeffrey M. Holzbeierlein, Peter Van Veldhuizen, J. Brantley Thrasher

    Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by deleterious side effects. Immunotherapy represents a valuable alternative to conventional treatments by inducing tumour-specific immune responses that control the growth of cancer cells. Sipuleucel-T is approved by the FDA as an immunotherapeutic agent for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC). Although this approval has raised cost-versus-benefit issues, it has provided proof of concept for the therapeutic potential of active immunotherapy approaches for metastatic CRPC. Numerous clinical studies have demonstrated clinical benefit using immunotherapy compared to traditional chemotherapy and several active immunotherapy approaches (at various developmental stages)have demonstrated the potential to change the face of prostate cancer treatment.


  • Open Access

    Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer

    by Seema Dubey, Peter Vanveldhuizen, Jeffrey Holzbeierlein, Ossama Tawfik, J. Brantley Thrasher, Dev Karan

    Macrophage inhibitory cytokine-1 (MIC-1), also known as prostate-derived factor (PDF), is a molecule of the TGF-β superfamily and has been associated with the progression of various types of diseases including prostate cancer. Initially identified from activated macrophages, the MIC-1 gene may provide a potential link between inflammation and prostate cancer. In this context, we performed MIC-1 expression analysis using mouse prostate tissues to determine whether there was any correlation with age and inflammation. Reverse transcription PCR analysis on RNA samples isolated from prostate lobes from prostate-specific antigen transgenic mice of varying ages revealed that MIC-1 gene expression is extremely low to non-detectable in the prostate tissues obtained from young mice, while its expression increases in the prostate tissues harvested from elderly mice. Increased MIC-1 gene expression in the mouse prostate was found to be associated with an increased level of infiltrating lymphocytes. To confirm this observation, we showed that inflammation-associated cytokines (IL-1β and TNF-α) significantly upregulate the secretion of the MIC-1 protein in a human prostate cancer cell line (LNCaP cells), while cytokines IL-6 and granulocyte macrophage colony-stimulating factor were less effective. Taken together, these data indicated that inflammation-associated cytokines may play a critical role in the functional regulation of the MIC-1 gene in the early stages of prostate cancer development. More studies are required to understand the biological activity of MIC-1 gene regulation in the development and progression of prostate cancer.


  • Dual Antigen Target-Based Immunotherapy for Prostate Cancer Eliminates the Growth of Established Tumors in Mice

    by Dev Karan, Seema Dubey, Peter Van Veldhuizen, Jeffrey M Holzbeierlein, Ossama Tawfik, J Brantley Thrasher

    Aims: We have previously shown that immunization with an adenovirus vector carrying an individual antigen induces antigen-specific CD8 T cells actively engaged in the destruction of tumor cells expressing the cognate antigen. In order to expand the range of antitumor responses beyond an individual antigen, we designed a recombinant adenovirus type 5 (rAd5) carrying a fusion construct of two full-length antigens. We used this adenovirus vector to test the concept that multiantigenic effector T cells could be generated simultaneously following a single immunization. Method: To perform the rAd5 constructs, we selected a combination of prostate-specific antigen (PSA) and prostate stem cell antigen (PSCA) genes based on their restricted distribution within the prostate tissue and their association with the development and progression of prostate cancer. Results: Immunization of mice with rAd5 vector carrying a fusion construct of PSA and PSCA (Ad5-PSA/PSCA) simultaneously induced the expansion of anti-PSA and anti-PSCA CD8 T cells, as measured by intracellular cytokine staining for IFN-gamma. The antigen-specific T-cell responses that developed were efficient in eliminating the target cells expressing cognate antigens measured by an in vivo cytotoxic T-cell assay. The in vivo tumor growth study showed that immunization of mice with Ad5-PSA/PSCA vaccine induced strong antitumor immunity when challenged with mouse prostate tumor cell lines (RM11) expressing human PSA (RM11/PSA). To further analyze the impact on therapeutic efficacy of Ad5-PSA/PSCA vaccine against the tumor cells expressing PSA and PSCA (RM11-PSA/PSCA) antigens, we injected mice with Ad5-PSA/PSCA vaccine. The vaccine inhibited the growth of established tumors with 80% of the mice becoming tumor free. These data provide useful information that antigen-specific effector T cells can be generated simultaneously and that their additive antitumor effect has the potential to eliminate the growth of established tumors. Therefore, the immunotherapy approach of using the simultaneous targeting of dual antigens associated with prostate cancer may have important implications for human clinical trials.


  • Open Access

    Macrophage Inhibitory Cytokine-1: Possible Bridge Molecule of Inflammation and Prostate Cancer

    by Dev Karan, Jeffrey Holzbeierlein, J. Brantley Thrasher

    There is emerging evidence that inflammation may lead to prostate cancer development. Although inflammation is an essential response to injury or infection, chronic inflammation is harmful and causes tissue damage. Increasing evidence suggests that inflammation leads to the development of epithelial cancers; however, studies on inflammation-targeted genes that might contribute to the development of cancer are at the beginning stage. Here, we describe macrophage inhibitory cytokine-1, which provides a potential link between inflammation and prostate cancer. Understanding the regulation of macrophage inhibitory cytokine-1 in response to inflammation may have potential for novel therapeutic strategies. [Cancer Res 2009;69(1):2–5]


  • Prostate cancer: genes, environment, immunity and the use of immunotherapy

    by D Karan, J B Thrasher, D Lubaroff

    Prostate cancer remains the most prevalent noncutaneous cancer, leading to almost 30 000 deaths every year in men in the United States. A large body of knowledge emphasizes a strong influence of epidemiological factors such as lifestyle, environment and diet, on the development of prostate cancer. Although risk reduction of prostate cancer has been somewhat successful, effective prevention is still lacking. Immunotherapeutic approaches, although moderately complicated, remain promising in an effort to control the progression and development of the disease. Taken together, the parameters of epidemiological studies and immunotherapeutic regimens might eventually be the most effective and preventive approach for prostate cancer. This review highlights some of the events associated with the development and prevention of prostate cancer.